Neobody
Pre-clinical- Indications
- COVID-19, Blood cancer
Company intelligence / Profile preview
No publicly available clinical trial results yet; all lead candidates are in preclinical stages. The company has developed several high-affinity neutralizing antibodies against SARS-CoV2 with broad epitope coverage designed to prevent viral escape mutations. They also launched a COVID‑19 antigen rapid test in partnership with other biotech firms[1][2][4][5].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AnTaimmu BioMed Co., Ltd..